Lexanopadol

Lexanopadol
Clinical data
Other namesGRT-6006; GRT6006; GRT-13106-G; GRT-13106G; GRT13106G
Routes of
administration		Oral[1]
Drug classμ-Opioid receptor agonist; Nociceptin receptor agonist; Analgesic
ATC code
  • None
Identifiers
  • 6-fluoro-N-methyl-1'-phenylspiro[4,9-dihydro-3H-pyrano[3,4-b]indole-1,4'-cyclohexane]-1'-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H25FN2O
Molar mass364.464 g·mol−1
3D model (JSmol)
  • CNC1(CCC2(CC1)C3=C(CCO2)C4=C(N3)C=CC(=C4)F)C5=CC=CC=C5
  • InChI=1S/C23H25FN2O/c1-25-22(16-5-3-2-4-6-16)10-12-23(13-11-22)21-18(9-14-27-23)19-15-17(24)7-8-20(19)26-21/h2-8,15,25-26H,9-14H2,1H3
  • Key:AMXGKMSRYLZAEO-UHFFFAOYSA-N

Lexanopadol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known by its developmental code name GRT-6006, is an opioid receptor modulator which was under development for the treatment of pain.[1][2][3] It is taken orally.[1] The drug acts as a dual agonist of the μ-opioid receptor and nociceptin receptor.[1][2][3] It is thought that the combination of these activities may confer enhanced analgesic efficacy.[3] Lexanopadol was under development by Grünenthal.[1][2] It reached phase 1 or 2 clinical trials prior to the discontinuation of its development, with no further development reported by 2016.[1][2] The drug was a follow-on compound to cebranopadol (GRT-6005).[3][4]

See also

References

  1. ^ a b c d e f "Lexanopadol". AdisInsight. 20 August 2018. Retrieved 9 January 2026.
  2. ^ a b c d "Delving into the Latest Updates on Lexanopadol Hemicitrate with Synapse". Synapse. 19 November 2025. Retrieved 9 January 2026.
  3. ^ a b c d Hans GH (2013). "Buprenorphine in the Treatment of Neuropathic Pain". In Ko MC, Husbands SM (eds.). Research and Development of Opioid-Related Ligands. ACS Symposium Series. Vol. 1131. Washington, DC: American Chemical Society. pp. 103–123. doi:10.1021/bk-2013-1131.ch006. ISBN 978-0-8412-2782-8. Recently, Grünenthal and Forest Laboratories have entered into a license agreement for the co-development of a novel oral small-molecule analgesic, GRT 6005, and its follow-on compound GRT 6006 (98–100). Both compounds were discovered and developed by Grünenthal and represent novel first in class molecules with unique pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 and 6006 are novel first in class compounds with potent agonist activity on ORL-1 (opioid receptor like -1) and the well established mu opioid receptor. Preliminary evidence (93, 100, 101) suggests that targeting ORL-1 receptors may have synergistic effects with mu receptors hence enhancing the therapeutic profile of the compounds in the treatment of pain.
  4. ^ "Forest Laboratories and Gruenenthal Enter Into Licensing Agreement for the Development and Commercialization of Novel Anal". Fierce Biotech. 6 December 2010. Retrieved 9 January 2026.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.